Saunders Timothy R, Psaltis Gregory, Weston John F, Yanase Rex R, Rogy Siegfried S, Ghalie Richard G
Department of Restorative Sciences, Herman Ostrow School of Dentistry of the University of Southern California, Los Angeles, California, USA.
Compend Contin Educ Dent. 2011 Jun;32(5):58-62.
This study investigated the pattern of use, dentist evaluation, and patient assessment of OraVerse (OV), a solution of phentolamine mesylate formulated for intraoral submucosal injection and used for the reversal of soft anesthesia after dental procedures. Participants were provided the drug for treatment of up to 10 patients each and agreed to complete a 26-item evaluation questionnaire at the end of the clinical assessment. Data were available from 51 dentists reporting on 390 patients 4 to 90 years of age. A total of 394 dental procedures were performed: 224 (57%) in the mandible and 170 (43%) in the maxilla. Local anesthetics most frequently used were lidocaine/epinephrine (66.4%) and articaine/epinephrine (23.6%). In 81.5% of cases, OV was administered after restorative procedures. This OV dose was given as one-half, one, and two cartridges in 11.8%, 76.7%, and 10.3% of patients, respectively. An adverse reaction at the injection site was reported in 19 patients (4.9%). The median times to return to normal after injection were 60 minutes for lip sensation, 57.5 minutes for tongue sensation, and 60 minutes for oral function. Patients reported reduced duration of oral numbness (92%) and improved dental experiences (84%) after use. A total of 83% of patients said they would recommend the medication to others and 79% said they would opt for OV in the future. Dentists reported that the medication addressed an existing need (86%), met expectations (82%), was a practice differentiator (55%) and a practice builder (45%), and improved scheduling (29%). In this in-practice clinical evaluation, times to return to normal oral sensation and function after OV administration were consistent with those reported in randomized clinical studies. Both patient and dentist satisfaction rates were high.
本研究调查了奥来可韦（OV）的使用模式、牙医评价及患者评估情况。奥来可韦是一种甲磺酸酚妥拉明溶液，用于口腔黏膜下注射，可逆转牙科手术后的软组织麻醉。为每位参与者提供了用于治疗多达10名患者的药物，并要求他们在临床评估结束时完成一份包含26个项目的评估问卷。数据来自51位牙医对390名年龄在4至90岁患者的报告。共进行了394次牙科手术：下颌手术224例（57%），上颌手术170例（43%）。最常使用的局部麻醉剂是利多卡因/肾上腺素（66.4%）和阿替卡因/肾上腺素（23.6%）。在81.5%的病例中，OV在修复手术后使用。分别有11.8%、76.7%和10.3%的患者接受的OV剂量为半支、1支和2支药筒。19名患者（4.9%）报告了注射部位的不良反应。注射后恢复正常的中位时间为：唇部感觉60分钟，舌部感觉57.5分钟，口腔功能60分钟。患者报告使用后口腔麻木持续时间缩短（92%），牙科体验改善（84%）。共有83%的患者表示会向他人推荐该药物，79%的患者表示未来会选择使用OV。牙医报告称，该药物满足了现有需求（86%），达到了预期（82%），是一种业务差异化因素（55%）和业务促进因素（45%），并改善了日程安排（29%）。在本次临床实践评估中，OV给药后恢复正常口腔感觉和功能的时间与随机临床研究报告的一致。患者和牙医的满意度都很高。
